Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Elevated in Acute Coronary Syndrome

Hayashida, Kazutaka; Kume, Noriaki; Murase, Takatoshi; Minami, Manabu; Nakagawa, Daisuke; Inada, Tsukasa; Tanaka, Masaru; Ueda, Akira; Kominami, Goro; Kambara, Hirofumi; Kimura, Takeshi; Kita, Toru

doi:10.1161/circulationaha.104.468397

Cited by 222 publications

(93 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the role of sLOX‐1 as a biomarker in ischemic heart disease is thoroughly evaluated. Indeed, in CAD, several studies imply that sLOX‐1 has potential as a sensitive biomarker for acute coronary syndrome14, 15, 16, 17, 18 and appears to be significantly higher in acute coronary syndrome than in stable CAD 14, 18. sLOX‐1 is also associated with coronary in‐stent restenosis in patients with stable CAD19 as well as with increased risk of periprocedural myocardial infarction in stable CAD patients undergoing elective percutaneous coronary intervention 20.…”

Section: Discussionmentioning

confidence: 99%

Increased Levels of Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor‐1 in Ischemic Stroke and Transient Ischemic Attack

Skarpengland

Skjelland

Kong

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundSoluble lectin‐like oxidized low‐density lipoprotein receptor‐1 (sLOX‐1) has been shown to be increased in patients with acute ischemic stroke. Here, we evaluated plasma sLOX‐1 levels and vascular carotid plaque LOX‐1 (ie, OLR1) gene expression in patients with ischemic stroke and transient ischemic attack (TIA) with particular focus on their relation to time since symptom onset.Methods and ResultsPlasma sLOX‐1 (n=232) and carotid plaque OLR1 gene expression (n=146) were evaluated in patients who were referred to evaluation for carotid endarterectomy, as well as in healthy control plasma (n=81). Patients were categorized according to presence of acute ischemic stroke or transient ischemic attack (n=35) ≤7 days, >7 days ≤3 months (n=90), >3 months (n=40), or no reported symptoms before study inclusion (n=67). Our major findings were the following: (1) Patients with carotid atherosclerosis had increased plasma sLOX‐1 levels as compared with controls. (2) Plaque OLR1 mRNA levels were increased in carotid plaques (n=146) compared with nonatherosclerotic vessels (ie, common iliac arteries of organ donors, n=10). (3) There were no differences in sLOX plasma levels or OLR1 gene expression when analyzed according to the time since relevant cerebral ischemic symptoms. (4) Also patients with severe carotid atherosclerosis without any previous ischemic events had raised sLOX‐1 levels. (5) Immunostaining showed colocalization between LOX‐1 and macrophages within the carotid plaques. (6) Also patients with acute stroke (within 7 days) caused by atrial fibrillation (n=22) had comparable raised sLOX‐1 levels.Conclusions sLOX‐1 levels are elevated in patients with ischemic stroke and transient ischemic attack independent of cause and time since the ischemic event.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased Levels of Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor‐1 in Ischemic Stroke and Transient Ischemic Attack

Skarpengland

Skjelland

Kong

et al. 2018

JAHA

View full text Add to dashboard Cite

show abstract

“…Kita & al demonstrated the important role that oxidized LDLs play in the pathogenesis of atherosclerosis and, as the major endothelial receptor for these; LOX-1 mediates the vast majority of the toxic effects of oxidized LDL [17]. A role of LOX-1 in atherosclerosis is also demonstrated by the fact that this receptor also acts as an adhesion molecule for activated platelets and mononuclear cells [2,18] and could thus promote the recruitment of inflammatory cells and vascular thrombosis. To our knowledge, this study is the only one in our regions to have studied this receptor in sickle-cell anemia, but a preliminary study carried out in our laboratory had found higher levels of LDL oxidized in sickle-cell patients [19].…”

Section: Discussionmentioning

confidence: 99%

“…In addition to its role in atherosclerosis, LOX-1 also acts in the inflammatory process. Indeed, recent studies have shown that LOX-1 is involved in the activation of inflammatory processes and inflammation-related disorders [1][2][3][4][5]. Like most surface receptors, LOX-1 can be released in soluble form by proteolytic cleavage and this soluble form (sLOX-1) could be a serum marker in the monitoring of oxidative and/or inflammatory diseases such as sickle-cell disease.…”

Section: Introductionmentioning

confidence: 99%

Elevated Soluble Lectin-like oxidized LDL Receptor 1 (sLOX1) levels in sickle cell patients

2017

ajbpr

View full text Add to dashboard Cite

Sickle-cell disease is characterized by chronic oxidative stress status with the resulting intense lipid peroxidation, and among the generated metabolites is the oxidized LDL. The latter thus modified are no longer recognized by the native receptors of LDL but by other types of receptors called "scavenger receptors", among which are LOX-1 (lectin-like oxidized LDL receptor). The capture of oxidized LDLs by vascular cells via scavenger receptors is a crucial step in the initiation and progression of atherosclerosis. Like most surface receptors, LOX-1 can be released in soluble form by proteolytic cleavage and this soluble form (sLOX-1) could be a serum marker in the monitoring of oxidative and/or inflammatory diseases such as Sickle cell disease. The objective of this work is to evaluate serum levels of sLOX-1 in sickle-cell patients and compare them to a control population. Our study involved 80 subjects, including 48 sickle-cell anemia and 32 controls. sLOX-1 was quantified using an Elisa method according to the manufacturer's instructions (Cloud-Clone Corp, Houston, USA) and other biochemical parameters on the Cobas 6000 (Roche, Mannheim, Germany). Our results showed serum levels of sLOX-1 significantly higher in sickle-cell patients population compared to controls (p <0.05). Moreover, sickle-cell patients had a higher risk of having increased sLOX1 (OR = 1.23).The high levels of sLOX-1 found in our study confirm our hypothesis and may reflect an increase in LOX-1 receptor expression during sickle-cell anemia.

show abstract

“…The proinflammatory cytokine IL-18 increased the cleavage of soluble human LOX-1 by 3-4-fold in a concentration-and time-dependent fashion in human embryonic kidney cells transfected with LOX-1 cDNA [96]. Hayashida and colleagues [97] measured soluble LOX-1 in the serum of patients undergoing coronary angiography and found elevated levels in patients with acute coronary syndromes. The increase was observed at an earlier stage of acute coronary syndrome than were other cardiac makers.…”

Section: Lox-1 Protein Structurementioning

confidence: 99%

Lectin-Like Oxidized Low Density Lipoprotein Receptor 1 (LOX-1) in Atherogenesis: A Brief Review

Reiss¹,

Anwar²,

Wirkowski³

2009

CMC

View full text Add to dashboard Cite

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a scavenger receptor that primarily binds and regulates oxidized low-density lipoprotein (LDL). Expression of LOX-1 is regulated by a feed-forward system stimulated by oxidized LDL (oxLDL), a major component of atherosclerosis. LOX-1 is a homodimer with a reactive backbone that can bind to a host of different ligands, including small molecules, and whole cells. LOX-1 is involved in many intercellular, intracellular, and molecular processes that are atherogenic. LOX-1 levels are elevated within atherosclerotic plaques and its expression is induced by proinflammatory cytokines. The ability of LOX-1 to bind many different ligands and control several atherogenic processes makes this receptor a likely vascular disease biomarker as well as an ideal choice for drug therapy aimed at preventing cardiovascular disease.

show abstract

Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Elevated in Acute Coronary Syndrome

Cited by 222 publications

References 58 publications

Increased Levels of Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor‐1 in Ischemic Stroke and Transient Ischemic Attack

Increased Levels of Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor‐1 in Ischemic Stroke and Transient Ischemic Attack

Elevated Soluble Lectin-like oxidized LDL Receptor 1 (sLOX1) levels in sickle cell patients

Lectin-Like Oxidized Low Density Lipoprotein Receptor 1 (LOX-1) in Atherogenesis: A Brief Review

Contact Info

Product

Resources

About